Cold weather got you feeling cooped up? The 2025 Newport Winter Festival is the perfect excuse to get out and have fun this ...

No matter the time of year, you and your special someone deserve an unforgettable getaway. Check out these five romantic ...

Despite the recent launch of congenital adrenal hyperplasia (CAH) drug Crenessity, Neurocrine Biosciences' disappointing ...

The pivotal clinical phase 3 trial for the olanzapine Long-Acting ... according to Medincell’s partner Teva, who finances and pilots the regulatory development of the product (mdc-TJK / TEV ...

Medincell to receive a $5 million development milestone payment from Teva with SOLARIS study completion ... The pivotal clinical phase 3 trial for the olanzapine Long-Acting Injectable (LAI ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

MONTPELLIER, France--(BUSINESS WIRE)--Medincell (Paris:MEDCL): ACCESS HERE THE FULL PRESS RELEASE David Heuzé Head of Corporate and Financial Communications, and ESG david.heuze@Medincell.com ...

Teva said the phase 2/3 ARTISTS 1 and phase 3 ARTISTS 2 true programme failed to meet their goals of primary endpoint of reduction of motor and phonic tics, as measured by a standard scale.

AXSM stock rises 20% as it settles Auvelity patent litigation with Teva, protecting the drug's exclusivity in the United States at least until Sept. 30, 2038. Shares in the brain drug developer ...

Armed with positive data from a phase 2b trial, Teva and Sanofi have decided to push their anti-TL1A antibody duvakitug into a phase 3 programme in inflammatory bowel disease (IBD). The results of ...